Trials / Completed
CompletedNCT00422994
A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole
An Open-Label, Parallel-Group, Repeat-Dose Study to Investigate the Effects of End Stage Renal Disease and Haemodialysis on the Pharmacokinetics of Ropinirole (Study RRL103628)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 79 Years
- Healthy volunteers
- Accepted
Summary
This study will investigate the effects of severe renal impairment and hemodialysis on the characteristics of the drug, ropinirole.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ropinirole dosing for up to 28 days |
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2006-12-01
- Completion
- 2006-12-01
- First posted
- 2007-01-17
- Last updated
- 2016-10-26
Locations
2 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT00422994. Inclusion in this directory is not an endorsement.